Back to table of contents Previous article Next article Government & LegalFull AccessPsychedelics Legislation Gains MomentumTerri D'ArrigoTerri D'ArrigoSearch for more papers by this authorPublished Online:16 Feb 2023https://doi.org/10.1176/appi.pn.2023.03.3.4AbstractBills that would decriminalize the use of psychedelics are popping up faster than magic mush...
Suicide is one of the leading causes of death amongst adolescents and decades of research have failed to curb suicide rates within this population. There is thus a need to better understand factors that correlate with adolescent suicidal thoughts and behaviors (STBs). MDMA/ecstasy and classic psychedelics represent two areas for exploration, as use of these ...
Alberta will soon become the first province to regulate psychedelic-assisted therapy. But, as with cannabis, momentum for medical access to psychedelics is outpacing research to guide their use. Earlier this year, Health Canada amended its Special Access Program to allow physicians to request
Importance: Psychedelic drugs are becoming accessible in the US through a patchwork of state legislative reforms. This shift necessitates consensus on treatment models, education and guidance for health care professionals, and planning for implementation and regulation. Objective: To assess trends in psychedelics legislative reform and legalization in the US...
Post-traumatic stress disorder (PTSD) is a significant public health concern for which existing therapies are only marginally effective. Indisputably, the primary line of treatment for PTSD is psychotherapy, according to current treatment guidelines. However, PTSD continues to be a chronic condition even after psychotherapy, with high psychiatric and medical...
Psilocybin recently received breakthrough status by the FDA for its use in treatment of depression. We therefore investigated mental health professionals' (MHPs) opinions on Psilocybin (n = 155). Overall, attitudes were neutral but self-rated knowledge of Psilocybin was low. The term used in the survey, 'Psilocybin' or 'Magic Mushrooms', did not significantl...
Ketamine, a non-competitive NMDA inhibitor with significant psychedelic properties, is widely used in the management of acute and chronic pain. Ketamine is used intraoperatively to spare opioids and prevent acute and chronic postoperative pain; it is also used in patients with complex pain syndromes and patients with opioid tolerance. Medical cannabis is alr...
As the consumers push towards use of natural substances for whole body health increases, and as the dependence upon prescription drugs shows no abatement, substances such as psilocybin (magic mushrooms) have emerged as acceptable methods to treat ailments previously addressed by prescription drugs. In addition to medical solutions provided naturally, many of...
A49-year-old woman was diagnosed with an ER +, PR-, HER2 +, BRCA- invasive ductal carcinoma which progressed metastatically to include bone, liver, and lymph node involvement. Standardised care included a 26-month treatment period with targeted chemotherapy and a ketogenic diet. The patient also began a course of cannabinoid-based therapy, consisting initial...
Objective: The Royal Australian and New Zealand College of Psychiatrists (RANZCP) has positioned itself against medically controlled patient access (at this current time) to 3,4-methylenedioxymethamphetamine (MDMA) and psilocybin-assisted therapies in its Therapeutic Use of Psychedelic Substances Clinical Memorandum, May 2020. The main reason given by the RA...
Back to table of contents Previous article Next article ProfessionalFull AccessMarijuana, Hallucinogen Use Reach Historic Levels Among Young AdultsLinda M. RichmondLinda M. RichmondSearch for more papers by this authorPublished Online:30 Nov 2021https://doi.org/10.1176/appi.pn.2021.11.29AbstractChanges in the availability and social acceptability of hallucin...
Back to table of contents Previous article Next article ViewpointsFull AccessPsychedelic Drugs for Mental Disorders and Human Potential: Placebo or PanaceaDavid Hellerstein, M.D., Kevin Sabet, Ph.D., Jeffrey A. Lieberman, M.D.David HellersteinSearch for more papers by this author, M.D., Kevin SabetSearch for more papers by this author, Ph.D., Jeffrey A. Lieb...
This study was undertaken to investigate migraine prevalence in persons with hallucinogen persisting perception disorder (HPPD) presenting as visual snow syndrome (VSS). Persons with visual snow as a persisting symptom after illicit drug use (HPPD) were recruited via a Dutch consulting clinic for recreational drug use. A structured interview on (visual) perc...
A psychedelic drug is one that “produces thought, mood and perceptual changes otherwise rarely experienced except in dreams, contemplative and religious exaltation, flashes of vivid involuntary memory, and acute psychosis”1. It does so “without causing physical addiction, craving, major physiological disturbances, delirium, disorientation or amnesia”1. The “...
Hallucinogenic mushroom is a kind of toxic strain containing psychoactive tryptamine substances such as psilocybin, psilocin and ibotenic acid, etc. The mushrooms containing hallucinogenic components are various, widely distributed and lack of standard to define, which made a great challenge to identification. Traditional identification methods, such as morp...
IntroductionCannabidiol (CBD) is purportedly a promising therapeutic agent to provide relief for a variety of medical conditions with mild or no psychoactive effects. However, little is known about young adults who use cannabis and CBD-dominant products, and associations between CBD use and other drug use.MethodsYoung adults (aged 24-32) who currently used c...
In 2020, Oregon voters legalized therapeutic psilocybin in response to a plethora of scientific studies showing symptom reduction for depression, anxiety, substance use disorders, opioid addictions, migraines, other mental illnesses, HIV/AIDS, and cancer. The legal rethinking regarding therapeutic psilocybin continues in both state legislatures and city coun...
BACKGROUND: While cannabis has a long history of spiritual use, its normalization in Western societies during the last decades has led to more recreational use. This study aimed to explore the characteristics of spiritual cannabis use as compared to recreational use and to the use of psychedelics such as LSD and psilocybin. METHODS: The study employed a mixe...
Back to table of contents Previous article Next article ProfessionalFull AccessJohns Hopkins Opens Research Center on PsychedelicsNick ZagorskiNick ZagorskiSearch for more papers by this authorPublished Online:28 Oct 2019https://doi.org/10.1176/appi.pn.2019.10a16AbstractA total of $17 million in private donations to the Hopkins center is expected to provide ...
